Literature DB >> 30511152

Association Between the Decline in Muscle Health and the Decline in Bone Health in Older Individuals from the SarcoPhAge Cohort.

Médéa Locquet1, Charlotte Beaudart2, Jean-Yves Reginster2,3, Olivier Bruyère2.   

Abstract

The longitudinal relationship between bone health and muscle health is scarcely explored. We aimed to explore the relationship between bone decline and muscle decline over 1 year in older individuals. We used data from the SarcoPhAge cohort, which aims to identify the consequences of sarcopenia. In this way, this study also highlights the yearly changes in muscle mass (by dual-energy absorptiometry), muscle weakness (by grip strength), and/or physical performance (by the short physical performance battery test). Measurements of areal bone mineral density (aBMD), enabling the diagnosis of osteoporosis, and bone microarchitecture (by means of the trabecular bone score) were also performed each year. A 1-year clinically relevant decline in bone and muscle health components was evidenced using the Edwards-Nunnally index. Among the 232 participants with complete data (75.5 ± 5.4 years, 57.8% women), we observed an association between a clinically relevant decline in the skeletal muscle mass index (SMI) and a decrease in aBMD (adjusted OR = 2.12 [1.14-2.51] for the spine, 2.42 [1.10-5.34] for the hip and 2.12 [1.04-5.81] for the neck), as well as a significant association between SMI and deterioration of the skeletal microarchitecture (aOR = 3.99 [2.07-7.70]). A clinically relevant decline in muscle strength was associated with a decrease in spine aBMD (aOR = 2.93 [1.21-7.12]) and hip aBMD (aOR = 3.42 [1.37-7.64]) only. The decline in muscle performance was related to the decline in bone microarchitecture only (aOR = 2.52 [1.23-5.17]). Individuals with incident sarcopenia had an approximately fivefold higher risk of concomitantly developing osteoporosis. A dynamic relationship between impaired muscle and bone health was observed, with an obvious association between the concomitant incidences of osteoporosis and sarcopenia.

Entities:  

Keywords:  Follow-up; Muscle strength; Osteoporosis; Physical performance; SarcoPhAge study; Sarcopenia

Mesh:

Year:  2018        PMID: 30511152     DOI: 10.1007/s00223-018-0503-4

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  6 in total

1.  Features of older community-dwelling adults with osteosarcopenia requiring support or care.

Authors:  Takahiro Shiba; Yohei Sawaya; Tamaki Hirose; Ryo Sato; Masahiro Ishizaka; Akira Kubo; Tomohiko Urano
Journal:  J Phys Ther Sci       Date:  2022-05-01

2.  Associations between osteoporosis, the severity of sarcopenia and fragility fractures in community-dwelling older adults.

Authors:  Ben Kirk; Steven Phu; Sharon L Brennan-Olsen; Ebrahim Bani Hassan; Gustavo Duque
Journal:  Eur Geriatr Med       Date:  2020-03-11       Impact factor: 1.710

Review 3.  Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly.

Authors:  Emanuela A Greco; Peter Pietschmann; Silvia Migliaccio
Journal:  Front Endocrinol (Lausanne)       Date:  2019-04-24       Impact factor: 5.555

4.  Sarcopenic osteoporosis, sarcopenic obesity, and sarcopenic osteoporotic obesity in the Camargo cohort (Cantabria, Spain).

Authors:  Paula Hernández-Martínez; José M Olmos; Javier Llorca; José L Hernández; Jesús González-Macías
Journal:  Arch Osteoporos       Date:  2022-07-29       Impact factor: 2.879

5.  Association between Geriatric Nutrition Risk Index and Skeletal Muscle Mass Index with Bone Mineral Density in Post-Menopausal Women Who Have Undergone Total Thyroidectomy.

Authors:  Tai-Hua Chiu; Szu-Chia Chen; Hui-Chen Yu; Jui-Sheng Hsu; Ming-Chen Shih; He-Jiun Jiang; Wei-Hao Hsu; Mei-Yueh Lee
Journal:  Nutrients       Date:  2020-06-05       Impact factor: 5.717

6.  Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers.

Authors:  Ben Kirk; Jesse Zanker; Gustavo Duque
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-03-22       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.